Try GOLD - Free
Deadly Silence: India's Negligent Pharma Manufacturing Units
Bio Spectrum
|August 2025
Indian pharma manufacturing units are a ticking time bomb. Inflammable chemicals that require special handling are often callously used by ignorant workers leading to reactions, reactor blasts and deaths. Above it, ill-designed setups and less knowledge of hardware and software are taking a toll on the industry. Showing a lackadaisical attitude towards the way manufacturing sites are being operated, Indian pharma companies are at the receiving end of various domestic and global regulators. Overlooking safety issues will lead to more catastrophic events.
-

India's growing pharma industry has a sordid tale to say. Amidst the hype of 'Pharmacy of the World,' discussions about tariffs and patent expiry leading to an opportunity for Indian pharma companies, hardly any discussions are held on the killer pharma manufacturing facilities. Unless and until something fatal happens.
A majority of the pharma companies seem to turn a blind eye to the lurking danger at its manufacturing sites across the country. So much so that lives are lost due to these catastrophic events.
Pharma manufacturing plants store chemicals, sometimes inflammable that are always at high risk. Reports of manufacturing plants not complying with safety standards are nothing new. Not following safety and other protocols becomes a free ride for the US FDA to issue warning letters. The US watchdog is notoriously known for issuing warning letters and somewhere the feeling comes that the agency does it right on certain occasions.
The Indian pharma industry has a history of incidents leading to deaths at manufacturing facilities with fire breakouts the common one.
Multiple incidents
The industry is marred with fire safety issues. Reports of fatality in pharma plants due to fire, inhaling toxic gas etc. happen quite often.
The recent blast at the Sigachi Industries plant at Pashamylaram in Telangana points out a disaster that is being compared with the Bhopal Gas Tragedy that happened way back in 1984. The powerful blast led to more than 40 dead and scores injured.
The management of Sigachi Industries was booked for culpable homicide. A criminal investigation is being pursued where there are allegations of gross negligence by the company. It is also being claimed that repeated warnings of outdated and unsafe machinery were ignored.
This story is from the August 2025 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size